CCSG Funds for Early Phase Clinical ResearchThe Lurie Cancer Center has funds are available to support early-phase clinical trials initiated by Lurie Cancer Center members through the Early Phase Clinical Research Support (EPCRS) mechanism of the Cancer Center Support Grant (CCSG). These funds are intended to support early phase clinical trials that will provide data that can be used as the basis for larger, later phase trials that are funded via competitive grant applications and industry.
Which studies are eligible?
- These should be high priority, innovative, pilot and phase 0 or I institutional clinical studies focusing on initial early phase testing of a candidate agent or device for the diagnosis, prevention detection or treatment of cancer.
- Studies must be conceptualized/designed by members of the Lurie Cancer Center’s research programs.
- Studies should typically be of short duration (e.g., one to two years).
- Supported studies must be approved by the PRMS.
- These funds may be used for global health studies, but must meet all eligibility criteria. In addition, NIH must track all projects in this category that include foreign components and, if necessary, State Department clearance must be obtained prior to implementation. OCC staff will act as the liaison between the Centers and the NIH Fogarty International Center, which is responsible for coordinating all clearances.
Studies receiving support through other peer-reviewed research grants, cooperative agreements or contracts are ineligible for support. Studies may receive partial support from industry, assuming all other criteria are met.
How can funds be used?Funds may not be used for any supervisory functions. Funding is limited to support of nurses and data managers for a pilot (pre-phase I) or phase I clinical trial or costs associated with generation of preliminary data through other early phase clinically related activities. For example:
- Purchase of imaging time for scans related to early phase clinical research
- Support for IND or IDE applications
- Pharmacodynamic studies (e.g., use of sequential or pre- and post- biopsies or assays of activity in peripheral tissues to identify investigational agents deserving full clinical development, clinical evaluation of structurally similar analogues directed at the same molecular target, determination of a dosing regimen for an agent to be used in combination therapy or development of novel imaging probes that establish mechanism of action in patient samples or provide functional and metabolic information about the effect of a drug on its target)
How can I apply?Please complete the EPCRS Application and submit it to Cary Passaglia and Renee Webb.
The Clinical Trials Office Oversight Committee will review the EPCRS application and inform applicants of its decisions. All approvals are contingent upon PRMS approval.Back to top